Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 139 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft August 5, 2019 EMA Recommends Extension of Indications for Enzalutamide April 2, 2021 Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease... July 21, 2025 Load more HOT NEWS The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... John Cena Set The Record For Most Make-A-Wish Visits And He... Study Examines Whether Blood Test Can Identify Early Cancers EMA Recommends Additional Extensions of Indications for Pembrolizumab
